Literature DB >> 16182769

Switch to tacrolimus for cyclosporine-induced gynecomastia in liver transplant recipients.

G Iaria1, L Urbani, G Catalano, P De Simone, P Carrai, S Petruccelli, L Morelli, L Coletti, C Garcia, R Liermann, F Mosca, F Filipponi.   

Abstract

We report herein on two male liver transplant (LT) recipients who presented with cyclosporine (CsA)-related gynecomastia 6 and 10 months after transplantation. The clinical workup showed increased luteinizing hormone (LH), associated with a slight reduction in testosterone blood levels in one patient and increased prolactin levels in the other. After excluding concomitant primary endocrine and/or malignant disease, conversion to tacrolimus (TAC) was performed resulting in clinical improvement of gynecomastia and return of hormone blood levels to normal range within 3 months. Our report confirms a putative role of CsA in post-LT gynecomastia, reversible however upon conversion to TAC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16182769     DOI: 10.1016/j.transproceed.2005.06.019

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

Review 1.  Gynecomastia and drugs: a critical evaluation of the literature.

Authors:  Frank Q Nuttall; Rohit S Warrier; Mary C Gannon
Journal:  Eur J Clin Pharmacol       Date:  2015-04-02       Impact factor: 2.953

Review 2.  Hormonal (Im)Balance and Reproductive System's Disorders in Transplant Recipients-A Review.

Authors:  Dagmara Szypulska-Koziarska; Kamila Misiakiewicz-Has; Barbara Wiszniewska
Journal:  Biology (Basel)       Date:  2021-03-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.